IP Library Granted Patent US 12,338,473
Granted Patent B2
US 12,338,473 · App. 18/207,453 · Granted Jun 24, 2025

Fermentative production of oligosaccharides by total fermentation utilizing a mixed feedstock

Inventors: Stefan Jennewein (Bad Honnef, DE); Dirk Wartenberg (Gau-Algesheim, DE); Katja Parschat (Bonn, DE)
Assignee: Chr. Hansen A/S
C12P19/12C12N1/20C12N9/1051C12N9/1205C12N9/16C12N9/90C12P19/04C12P19/18C12N2500/34C12Y204/01038C12Y207/01004C12Y207/01011C12Y207/01056C12Y207/07009C12Y301/03011C12Y501/03002C12Y504/02002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,338,473
App. No.
18/207,453
Granted
Jun 24, 2025
Kind
B2
Abstract

Disclosed are genetically engineered microbial cells for the production of oligosaccharides comprising a galactose-β1,4-glucose moiety at their reducing end, wherein said microbial cells are able to produce said oligosaccharides in the absence of exogenously added lactose, and a method of producing said oligosaccharides using said microbial cells.

Claims (20)

1. A genetically engineered microbial cell for the production of lactose or an oligosaccharide of interest which comprises a galactose-β1,4-glucose moiety at its reducing end, wherein said microbial cell is an Escheria coli cell and comprises:

at least one glucose transporter for translocating glucose from the culture medium into the microbial cell's cytoplasm such that free glucose becomes available for intracellular biosynthesis of lactose, wherein the at least one glucose transporter is selected from the group consisting of glucose facilitated diffusion proteins and glucose translocating permeases;

an UDP-galactose biosynthesis pathway comprising the activities of at least a phosphoglucomutase, an UTP-glucose-1-phosphate-uridyltransferase and an UDP-glucose-4-epimerase activity;

at least one β-1,4-galactosyltransferase being able to galactosylate free glucose to intracellularly produce lactose, wherein the β-1,4-galactosyltransferase is encoded by a gene selected from Neisseria meningitidis lgtB, Aggregatibacter aphrophilus lex-1, Pasteurella multocida galTpm 1141; and

wherein the glucokinase gene(s) of the microbial cell have been deleted or functionally inactivated.

2. The genetically engineered microbial cell according to claim 1 , wherein said microbial cell expresses or overexpresses at least one gene encoding the glucose transporter.

3. The genetically engineered microbial cell according to claim 1 , wherein said microbial cell comprises at least one additional glycosyltransferase.

4. The genetically engineered microbial cell according to claim 1 , wherein the microbial cell comprises a glucose-translocating phosphotransferase system.

5. The genetically engineered microbial cell according to claim 1 , wherein said microbial cell further comprises a fructose transporter.

6. The genetically engineered microbial cell according to claim 1 , wherein the microbial cell comprises a fructose specific phosphotransferase system, and wherein the microbial cell further comprises 1-phosphofructokinase.

7. The genetically engineered microbial cell according to claim 5 , wherein said microbial cell comprises fructokinase-6 activity and 6-phosphofructokinase-1 activity.

8. The genetically engineered microbial cell according to claim 6 , wherein the microbial cell comprises a fructose-1,6-bisphosphatase.

9. The genetically engineered microbial cell according to claim 6 , wherein said microbial cell comprises a deletion or functional inactivation of its glucose-6-phosphate isomerase.

10. The genetically engineered microbial cell according to claim 3 , wherein the additional glycosyltransferase is a fucosyltransferase, and wherein said microbial cell comprises a mannose-6-phosphate isomerase, a phosphomannomutase, a mannose-1-phosphate-guanylyltransferase, a GDP-mannose-4,6-dehydratase, and a GDP-L-fucose synthase.

11. The genetically engineered microbial cell according to claim 1 , wherein said microbial cell comprises an exporter protein or a permease exporting the oligosaccharide of interest from the cell.

12. A product comprising a genetically engineered microbial cell according to claim 1 , for production of lactose or an oligosaccharide of interest, wherein the lactose or oligosaccharide of interest comprises a galactose-β1,4-glucose moiety at its reducing end.

13. The genetically engineered microbial cell according to claim 1 , wherein the oligosaccharide of interest is a human milk oligosaccharide selected from 2′-fucosyl-latose, 3-fucosyllactose, 2′,3-difucosyllactose, 3′-sialyllactose, 6′-sialyllactose, 3-fucosyl-3′-sialyllactose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-difucosylhexose I, lacto-N-difucosylhexaose II, lacto-N-sialylpentaose LSTa, LSTb, and LSTc.

14. The genetically engineered microbial cell according to claim 2 , wherein the at least one gene encoding the glucose transporter is selected from glf, galP and functional variants thereof.

15. The genetically engineered microbial cell according to claim 3 , wherein the at least one additional glycosyltransferase is selected from fucosyltransferases, sialyltransferases, glucosaminyltransferases, and galactosyltransferases.

16. The genetically engineered microbial cell according to claim 11 , wherein the exporter protein or permease exporting the oligosaccharide of interest from the cell is a sugar efflux transporter.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: CHR. HANSEN HMO GMBH
To: CHR. HANSEN A/S
Reel/Frame 070396/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2024
From: JENNEWEIN, STEFAN; WARTENBERG, DIRK; PARSCHAT, KATJA
To: JENNEWEIN BIOTECHNOLOGIE GMBH
Reel/Frame 067007/0917 →
CHANGE OF NAME Recorded Apr 4, 2024
From: JENNEWEIN BIOTECHNOLOGIE GMBH
To: CHR. HANSEN HMO GMBH
Reel/Frame 067020/0360 →
Priority Claims (1)
EP 18192898 · Sep 6, 2018 · regional
Continuity (2)
Division 17273447
Related Publication 20230399669A1 · Dec 14, 2023
References Cited (36)
US 7521212B1 · Samain et al. · 2009 [cited by applicant]
US 20110207187A1 · Tokuda et al. · 2011 [cited by applicant]
US 20140349348A1 · Beauprez et al. · 2014 [cited by applicant]
US 20210317493A1 · Jennewein et al. · 2021 [cited by applicant]
US 20230399669A1 · Jennewein · 2023 [cited by examiner]
EP 3315610A1 · 2018 [cited by applicant]
KR 20170003546A · 2017 [cited by applicant]
RU 2016121174C2 · 2020 [cited by applicant]
WO 2006034225A2 · 2006 [cited by applicant]
WO 2015066551A2 · 2015 [cited by applicant]
WO 2015150328A1 · 2015 [cited by applicant]
WO 2015197082A1 · 2015 [cited by applicant]
Albermann et al., “Synthesis of the milk oligosacaride 2′-fucosyllactose using recombinant bacterial enzymes”, Carbohydrate Rese (2001) 334(2): 97-103. [cited by applicant]
Bäcklund, “Impact of glucose uptake rate on recombinant protein production in [cited by applicant]
Bidossi et al., “A functional genomics approach to establish the complement of carbohydrate transporters in [cited by applicant]
Crigler et al., “Glucose can be transported and utilized in [cited by applicant]
Curtis et al., “Phosphorylation of D-glucose in [cited by applicant]
Fordjour et al., “Metabolic engineering of [cited by applicant]
GenBank Accession No. AAA27691.1, Apr. 26, 1993, 1 page. [cited by applicant]
GenBank Accession No. ANK03259.1, Jun. 16, 2016, 2 pages. [cited by applicant]
GenBank Accession No. AUY31240.1, Mar. 2, 2018, 2 pages. [cited by applicant]
International Search Report for Application No. PCT/EP2019/073363 mailed Nov. 13, 2019. [cited by applicant]
Luo et al., “The transport and mediation mechanisms of the common sugars in [cited by applicant]
Mara Grube et al., “Hydrogen-producing [cited by applicant]
R. E. Huber, et al., “Efflux of beta-galactosidase products from [cited by applicant]
Zheng et al., “The Prototypical H+/Galactose Symporter GaIP Assembles into Functional Trimers,” J Mol Biol., 2010, 396(3):593-601. [cited by applicant]
Kornberg et al., 2000, Proceedings of the National Academy of Sciences (PNAS), 97, 1808-1812. [cited by applicant]
Jahreins et al., 2008, FEMS Microbiol Review Article, 32, 891-907. [cited by applicant]
Mao et al., 2006, Biotechnol, 22, 369-374. [cited by applicant]
Baumgärtner et al., 2015, Enzyme and Microbial Technology, 75-75, 37-43. [cited by applicant]
Ruffing et al., 2006, Microbial Cell Factories, 5, 4-9. [cited by applicant]
Hines et al., 2007, The Journal of Biological Chemistry, 282, 11696-11704. [cited by applicant]
Petschacher et al., 2016, The Journal of Biotechnology, 235, 61-83. [cited by applicant]
Liu et al., 1999, The Journal of Biological Chemistry, 274, 22977-22984. [cited by applicant]
Akselsen et al., 2024, Supporting data for opposition against Chr. Hansen patent EP 3620510. [cited by applicant]
Parschat et al., 2020, ACS Synthetic Biology, 9, 2784-2796. [cited by applicant]